ATE378418T1 - Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen - Google Patents

Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen

Info

Publication number
ATE378418T1
ATE378418T1 AT99953081T AT99953081T ATE378418T1 AT E378418 T1 ATE378418 T1 AT E378418T1 AT 99953081 T AT99953081 T AT 99953081T AT 99953081 T AT99953081 T AT 99953081T AT E378418 T1 ATE378418 T1 AT E378418T1
Authority
AT
Austria
Prior art keywords
rage
peptide
interaction
compound
inhibiting
Prior art date
Application number
AT99953081T
Other languages
English (en)
Inventor
Ann Schmidt
David Stern
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/167,705 external-priority patent/US7081241B1/en
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of ATE378418T1 publication Critical patent/ATE378418T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
AT99953081T 1998-10-06 1999-10-06 Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen ATE378418T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/167,705 US7081241B1 (en) 1998-10-06 1998-10-06 Extracellular rage binding protein (EN-RAGE) and uses thereof
US09/263,312 US6555340B1 (en) 1998-10-06 1999-03-05 Nucleic acid encoding bovine extracellular rage binding protein (en-rage)

Publications (1)

Publication Number Publication Date
ATE378418T1 true ATE378418T1 (de) 2007-11-15

Family

ID=26863404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953081T ATE378418T1 (de) 1998-10-06 1999-10-06 Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen

Country Status (9)

Country Link
US (3) US6670136B2 (de)
EP (1) EP1121454B1 (de)
JP (1) JP2002526117A (de)
AT (1) ATE378418T1 (de)
AU (1) AU765719B2 (de)
CA (1) CA2346217A1 (de)
ES (1) ES2299267T3 (de)
HK (1) HK1041293B (de)
WO (1) WO2000020621A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6482932B1 (en) * 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6528640B1 (en) * 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
AU2002245591B2 (en) 2001-03-05 2007-05-17 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CA2440037C (en) 2001-03-05 2010-02-16 Transtech Pharma, Inc. Benzimidazole derivatives for modulating the rage receptor
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
ES2373875T3 (es) 2002-03-05 2012-02-09 Transtech Pharma, Inc. Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage.
CN1774445A (zh) * 2002-08-16 2006-05-17 惠氏公司 用于治疗rage相关病症的组合物和方法
CA2520515C (en) 2003-03-28 2012-08-28 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005026209A2 (en) 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
UA93356C2 (ru) 2004-08-03 2011-02-10 Tpahctek Фарма, Инк. Белки слияния ha ochobe rage и способы их использования
UA92154C2 (ru) * 2004-08-03 2010-10-11 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
US20090220484A1 (en) * 2005-03-17 2009-09-03 Ann Marie Schmidt Rage/Diaphanous Interaction and Related Compositions and Methods
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
CA2634908C (en) * 2005-12-23 2015-05-19 Gcoder Systems Ab Positioning pattern
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
EP2021474A2 (de) 2006-05-05 2009-02-11 Transtech Pharma, Inc. Rage-fusionsproteine, formulierungen daraus und verfahren zu ihrer verwendung
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
CN101842382A (zh) 2007-06-14 2010-09-22 卡拉狄加制药公司 Rage融合蛋白
CN101903775A (zh) * 2007-10-19 2010-12-01 Erac股份有限公司 抗edta的s100a12c复合物(erac)
EP2789684B1 (de) 2008-05-23 2016-12-21 Siwa Corporation Verfahren und Zusammensetzungen zur erleichterten Regeneration
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
EP2572197A4 (de) * 2010-05-18 2013-08-28 Texas A & M Univ Sys Verfahren und zusammensetzungen zur diagnose und überwachung von entzündungskrankheiten
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012170358A1 (en) * 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Methods relating to s100a12 for diagnosing infectious diseases and kit therefor
US9175062B2 (en) * 2012-01-03 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing human sRAGE, and treatment methods using sRAGE
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
IL251210B2 (en) 2014-09-19 2023-12-01 Siwa Corp Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
WO2018015375A1 (en) 2016-07-20 2018-01-25 Westfälische Wilhelms-Universität Münster Complex-specific standardization of immunological methods for the quantification of s100a12
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731166A3 (de) * 1995-03-06 1997-12-29 Tonen Corporation Neue Calcium-bindende Proteine
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US5688653A (en) * 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AU6766800A (en) * 1999-08-13 2001-03-13 Trustees Of Columbia University In The City Of New York, The Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1660014A4 (de) * 2003-09-05 2009-07-22 Univ Columbia Rage-verwandte verfahren und zusammensetzungen zur behandlung von glomerulären schäden
WO2005042032A1 (en) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for treating multiple sclerosis
WO2005042782A1 (en) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for reducing seizure-induced neuronal damage
UA92154C2 (ru) * 2004-08-03 2010-10-11 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
US20090220484A1 (en) * 2005-03-17 2009-09-03 Ann Marie Schmidt Rage/Diaphanous Interaction and Related Compositions and Methods
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases

Also Published As

Publication number Publication date
HK1041293B (zh) 2008-01-25
US20040121372A1 (en) 2004-06-24
WO2000020621A1 (en) 2000-04-13
JP2002526117A (ja) 2002-08-20
US20090228997A1 (en) 2009-09-10
EP1121454B1 (de) 2007-11-14
EP1121454A1 (de) 2001-08-08
EP1121454A4 (de) 2005-05-11
AU6510099A (en) 2000-04-26
CA2346217A1 (en) 2000-04-13
HK1041293A1 (en) 2002-07-05
US6670136B2 (en) 2003-12-30
ES2299267T3 (es) 2008-05-16
AU765719B2 (en) 2003-09-25
US20020106726A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
ATE378418T1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
EP1903058A3 (de) Extrazelluläres neues RAGE-bindendes Protein (EN-RAGE) und dessen Verwendung
Svenningsen et al. Plasmin in nephrotic urine activates the epithelial sodium channel
Azzu et al. Degradation of an intramitochondrial protein by the cytosolic proteasome
Carbotti et al. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors
Scholl et al. New insights into aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K:+: channel: KCNJ5
Murphy et al. Quantification of calsequestrin 2 (CSQ2) in sheep cardiac muscle and Ca2+-binding protein changes in CSQ2 knockout mice
DE60315296D1 (de) Zell-selektives Abgabe System
HK1040533A1 (zh) 監察蛋白脢體抑制劑藥物活動的方法
Dendorfer et al. Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats
WO2007047754A3 (en) Mtor pathway theranostic
DE69333726T8 (de) Glucagonrezeptoren
Contucci et al. Statherin levels in saliva of patients with precancerous and cancerous lesions of the oral cavity: a preliminary report
EP1102988B8 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
GB9924957D0 (en) Novel treatment
Cervia et al. Pharmacological characterisation of native somatostatin receptors in AtT‐20 mouse tumour corticotrophs
Pelá et al. Proteomic profiles of the acquired enamel pellicle formed in vitro, in situ, or in vivo
Bianchini et al. Cytosolic [Ca2+] homeostasis and tyrosine phosphorylation of phospholipase C gamma 2 in HL60 granulocytes.
Todorov et al. Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle
MXPA02012257A (es) Uso de un antagonista de aldosterona para el tratamiento o profilaxis de efectos patogenicos mediados por aldosterona.
Blaukat et al. Downregulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure
Beretta et al. Glycyl-histidyl-lysine (GHK) is a quencher of α, β-4-hydroxy-trans-2-nonenal: a comparison with carnosine. Insights into the mechanism of reaction by electrospray ionization mass spectrometry, 1H NMR, and computational techniques
DK0862627T3 (da) Neuropeptid Y-Y5 receptor
Randazzo et al. Synthesis of C1 inhibitor (C1-INA) by a human monocyte-like cell line, U937.
DK0788512T3 (da) Proinsulinpeptidforbindelser til detektion og behandling af Type I-diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121454

Country of ref document: EP